Experts Redesign CRISPR to Engineer Massive Quantities of CellsSeptember 7, 2022
Nature Biotechnology reports a new version of the CRISPR-Cas9 gene editing system that eases the process of re-engineering large amounts of cells for therapeutic applications. The technique, designed by Gladstone Institutes and the University of California, San Francisco (UCSF), allows scientists to introduce long DNA sequences to precise locations in the genomes of cells at significantly high efficiencies without the need for delivery systems.
"One of our goals for many years has been to put lengthy DNA instructions into a targeted site in the genome in a way that doesn't depend on viral vectors," said Dr. Alex Marson, Director of the Gladstone-UCSF Institute of Genomic Immunology and senior author of the new study. "This is a huge step toward the next generation of safe and effective cell therapies."
Aside from the description of the new technique, their paper also indicates how to generate CAR-T cells, which can help combat multiple myeloma and rewrite gene sequences where mutations can cause rare inherited immune diseases.
Read the original article from News-Medical.Net.
You might also like:
- FDA Approves CRISPR-based Therapeutic for Trial
- Soybean Cotyledon Used as Platform for Production of Therapeutic Proteins
- Pocket K No. 26: Molecular Pharming and Biopharmaceuticals
Biotech Updates is a weekly newsletter of ISAAA, a not-for-profit organization. It is distributed for free to over 22,000 subscribers worldwide to inform them about the key developments in biosciences, especially in biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
See more articles:
Research and Tools
- Cotton Gene Editing Project to Help Reduce Infestations and Pesticide Use
- International Project to Explore Gene Editing to Manage Salmon Lice
- Experts Redesign CRISPR to Engineer Massive Quantities of Cells
- CRISPR-Cas System with On-off Switch Cuts Proteins Instead of DNA
Policy Considerations and Approvals
- Experts Push for Organic-Biotech Partnership for Sustainable Agriculture
Public Acceptance and Engagement
- Study Defines Important Aspects in Communicating about Genome Editing in Europe
Read the latest:
- Biotech Updates (February 21, 2024)
- Gene Editing Supplement (February 14, 2024)
- Gene Drive Supplement (February 22, 2023)
Subscribe to BU: